SUZ12: A Potential Drug Target and Biomarker for Chromatin Precipitated E2F Target 9 Protein

Target Name: SUZ12

NCBI ID: G23512

SUZ12

SUZ12: A Potential Drug Target and Biomarker for Chromatin Precipitated E2F Target 9 Protein

Abstract:

SUZ12, a member of the E2F target 9 family, has been identified as a potential drug target and biomarker for various diseases. Its unique mechanism of inhibiting the activity of histone-modifying enzymes, as well as its ability to induce apoptosis in cancer cells, make it an attractive candidate for drug development. In this article, we will discuss the biology of SUZ12, its potential drug target and biomarker properties, and its current status as a research tool.

Introduction:

The E2F family of proteins plays a crucial role in the regulation of gene expression and DNA replication. E2F target 9 (SUZ12), a 21 kDa protein, is a subunit of the E2F2 complex and is involved in the recruitment of co-chaperones to promote DNA replication. The E2F2 complex is composed of three subunits: SUZ1, SUZ2, and SUZ3, which have distinct functions in regulating DNA replication. SUZ12, as a member of the E2F target 9 family, has been shown to play a critical role in the regulation of gene expression and cell growth.

SUZ12 has been shown to have a unique mechanism of inhibiting the activity of histone-modifying enzymes, such as histone H1 modifiers, which are involved in the regulation of gene expression. This mechanism of inhibition is based on the presence of a nucleotide-binding oligomerization domain (NBO domain) in SUZ12, which is involved in the inhibition of the activity of histone-modifying enzymes.

In addition to its mechanism of inhibition of histone-modifying enzymes, SUZ12 has also been shown to have a unique ability to induce apoptosis in cancer cells. This is based on the presence of the suicide gene P38, which is involved in the regulation of cell survival. When SUZ12 is overexpressed, it can induce apoptosis in cancer cells, suggesting that it may be a useful biomarker for cancer treatment.

Potential Drug Target and Biomarker Properties:

SUZ12's unique mechanism of inhibiting the activity of histone-modifying enzymes and its ability to induce apoptosis make it an attractive candidate for drug development. Its ability to inhibit the activity of histone-modifying enzymes makes it a potential target for drugs that target histone modification pathways. Additionally, its ability to induce apoptosis in cancer cells makes it a potential biomarker for cancer treatment, as apoptosis is a hallmark of cancer cell death.

Current Status:

The current status of SUZ12 research is focused on its potential drug target and biomarker properties. Several studies have shown that SUZ12 can inhibit the activity of histone-modifying enzymes, including the activity of histone H1 modifiers. In addition, several studies have shown that SUZ12 can induce apoptosis in cancer cells.

Despite its potential as a drug target and biomarker, the current status of SUZ12 research is limited. There are currently no approved drugs that target SUZ12, and there are no studies evaluating its potential clinical benefits. However, the potential of SUZ12 as a drug target and biomarker is an exciting area of research that may have significant implications for the treatment of various diseases.

Conclusion:

SUZ12 is a protein that has unique properties that make it an attractive candidate for drug development. Its ability to inhibit the activity of histone-modifying enzymes and induce apoptosis in cancer cells make it a potential target for drugs that target these pathways. Further research is needed to evaluate the potential of SUZ12 as a drug target and biomarker for various diseases.

Protein Name: SUZ12 Polycomb Repressive Complex 2 Subunit

Functions: Polycomb group (PcG) protein. Component of the PRC2 complex, which methylates 'Lys-9' (H3K9me) and 'Lys-27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene (PubMed:15225548, PubMed:15231737, PubMed:15385962, PubMed:16618801, PubMed:17344414, PubMed:18285464, PubMed:28229514, PubMed:29499137, PubMed:31959557). The PRC2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems (PubMed:12435631, PubMed:12351676, PubMed:15385962, PubMed:15099518, PubMed:15225548, PubMed:15684044, PubMed:16431907, PubMed:18086877, PubMed:18285464). Genes repressed by the PRC2 complex include HOXC8, HOXA9, MYT1 and CDKN2A (PubMed:15231737, PubMed:16618801, PubMed:17200670, PubMed:31959557)

The "SUZ12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SUZ12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets